UK-listed fund-of-funds manager SVG Capital has delivered a 14% return to shareholders in the financial year ending January 31, 2016, according to its annual results.

The return was driven by the strong performance of its post-2012 investment portfolio. These investments increased in value by 19% during the 12-month period, helped by growth from underlying portfolio companies and the 2015 realisations of two firms from the portfolio - Cinven's £2.3 billion sale of drug manufacturer AMCo and Clayton, Dubilier & Rice's $2.6 billion exit of PharMEDium.